Manuel López-Figueroa, Ph.D. is a neuroscientist, biotechnology executive, and investor with more than 25 years of experience spanning scientific research, venture capital, company formation, and strategic development in the life sciences.
Dr. López-Figueroa serves as Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research initiative involving Stanford University, the University of Michigan, Cornell University, the HudsonAlpha Institute for Biotechnology, and the University of California, Irvine.
Dr. López-Figueroa spent 25 years at Bay City Capital, a life sciences venture capital firm that has invested more than $1.6 billion across over 100 companies worldwide, where he served as Managing Director. His venture capital activities includes a more recent role as Operating Partner at Civilization Ventures, an early-stage investment firm focused on biotechnology and healthcare innovation.
He also serves as Lead Director and Chair of the Compensation and Nominations Committee of Oryzon Genomics (ORY.MC), a publicly traded biopharmaceutical company developing novel epigenetic therapies for central nervous system disorders and oncology.
Previously, Dr. López-Figueroa served as Chief Operating Officer of IMIDomics, a biotechnology company focused on immune-mediated inflammatory diseases that was acquired by UCB in 2026.
Dr. López-Figueroa completed his postdoctoral training at the University of Michigan and the University of Copenhagen. He holds a Ph.D. in Medicine and Surgery and an M.S. in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, respectively. He has also served on the boards of Zulia Biotech and Cantero Therapeutics, a BridgeBio Pharma subsidiary.